Danelle Johnston, MSN, RN, ONN-CG, OCN, of AONN+ Appointed to the Biden Cancer Initiative Advisory Committee

May 2018 Vol 9, No 5

Categories:

In the News
Kristin Siyahian

The Academy of Oncology Nurse & Patient Navigators (AONN+) is proud to announce the appointment of its Chief Nursing Officer and Senior Director of Strategic Planning and Initiatives, Danelle Johnston, MSN, RN, ONN-CG, OCN, to the Biden Cancer Initiative Advisory Committee.

The mission of the Biden Cancer Initiative is to develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research, and care, and to reduce disparities in cancer outcomes. Vice President Joe Biden and Dr Jill Biden, cochairs of the initiative’s Board of Directors, have assembled a leadership team of experts in the fields of medical research, patient care, information technology, finance, management, patient engagement, patient experience, and public policy. The initiative will work with patients and patient organizations, cancer researchers, cancer centers, research universities, governments, and the private and philanthropic sectors to identify and address the critical issues in cancer prevention, research, and care to drive new actions and collaborations toward ending cancer as we know it.

Through these collaborations, the initiative intends to create a renewed sense of urgency around the need to expedite cancer research, care resources, data sharing, and patient navigation. The goal? To reimagine how the government, academia, nonprofits, and the private sector can better organize their resources and systems to collaborate to take on cancer.

Ms Johnston recently attended a Biden Cancer Initiative Advisory Board meeting. “Participating in a national conversation on improving cancer care is a great honor. We are being asked to reconsider how we address cancer from prevention through survivorship. It’s a huge undertaking, but a very exciting one. I’m delighted to be a part of it.”

Related Articles
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Web Exclusives
Another Approval for Keytruda
April 16, 2019 – FDA Approvals, News & Updates
Web Exclusives
  • Another Approval for Keytruda and An Easing of Pregnancy Restrictions for Women Taking Soltamox
  • FDA Advises Women to Avoid Pregnancy for Only 2 Months After Final Dose of Soltamox
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Web Exclusives
On April 4, 2019, the US Food and Drug Administration (FDA) expanded the indication of palbociclib (Ibrance; Pfizer), a kinase inhibitor, in combination with specific endocrine therapies for men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This is the first hormonal-based therapy to be approved for men.
Cite this Article

Journal of Oncology Navigation & Survivorship. 2018;9:192.

Last modified: June 13, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code